Epitalon Half-Life & Stability
Part of the full Epitalon guide - a synthetic linear tetrapeptide reference compound, identity-verified with a COA on every vial.
In brief
Epitalon's pharmacokinetic and stability profile is best discussed by separating the few peptide-specific facts in this entry from the general handling principles that apply to any short synthetic peptide, because the provided data set does not include a measured half-life, clearance rate, or formal degradation kinetics for AEDG. What the entry does fix precisely are the molecular constants that govern stability reasoning: a low molecular weight of 390.35 g/mol, the formula C14H22N4O9, and a four-residue linear sequence (Ala-Glu-Asp-Gly) with no stabilizing cyclization, no non-natural residues noted, and no terminal modifications described. Small unmodified linear tetrapeptides are, as a class, expected to be vulnerable to peptidase activity and therefore short-lived in biological matrices, which is why so much of the cited research is conducted in controlled in-vitro systems where exposure can be maintained. This spoke frames stability around what the molecular specification supports, flagging clearly wherever a statement is a general peptide-class principle rather than an Epitalon-specific measurement.
The detail
A closer look
01
Why the entry supports no specific half-life value
No half-life, clearance, volume-of-distribution, or degradation constant for Epitalon is present in the provided data, so none should be asserted. The honest characterization is structural inference only: at 390.35 g/mol with four standard amino acids in an unprotected linear chain, AEDG fits the profile of a small peptide that is generally expected to be susceptible to rapid enzymatic hydrolysis in serum-containing or peptidase-rich environments. That is a class-level expectation, not a measured Epitalon value. The cited literature works around this by using cultured-cell and biochemical systems, where the peptide is applied directly to defined media and its molecular effects, nuclear penetration, DNA binding, hTERT induction, are read out under controlled conditions rather than inferred from a circulating concentration over time.
02
Stability and storage handling for laboratory stocks
Stability in the laboratory is governed by storage state more than by intrinsic half-life. As a general peptide-class practice, lyophilized material is the most stable form and is kept dry and cold per its certificate of analysis, while reconstituted aqueous stocks are more labile and benefit from refrigeration for short-term use and frozen aliquoting for longer storage. Repeated freeze-thaw cycling is minimized because it can degrade peptides and reduce assay reproducibility. The acidic glutamate and aspartate residues make AEDG water-soluble, which simplifies handling but does not by itself confer chemical stability. None of these storage parameters are Epitalon-specific numbers from the entry; they are standard short-peptide handling principles applied to a molecule whose specification (small, linear, unmodified) makes careful cold storage the prudent default.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Epitalon is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.